GAIN TOOLS Act of 2022
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in senate (Jan 11, 2022)
Generating Antibiotic Incentives Now Through Opening Opportunities to Leverage Science Act of 2022 or the GAIN TOOLS Act of 2022
This bill expands the definition of a qualified infectious disease product (QIDP) to include eligible biological products. Under current law, the first application (or supplement) for a specific product and indication to be designated a QIDP shall receive priority review for market approval by the Food and Drug Administration.
Generally, a biological product designated as a QIDP is one that acts on bacteria or fungi and is intended to treat a serious or life-threatening infection.
However, a biological product with a QIDP designation shall not receive the market exclusivity extension currently available to drugs that receive the designation.
What just happenedJan 11, 2022
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Who’s behind it
- Introduced in SenateJan 11, 2022
- Jan 11, 2022IntroReferral
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health, Education, Labor, and Pensions Committee - Jan 11, 2022IntroReferral10000
Introduced in Senate